Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 03.07.2026 FXGB LN IE00BD5HBR05 47,692.00 GBP 974,615.09 27.297  ...
-

Gloo Announces Proposed Public Offering of Class A Common Stock

BOULDER, Colo.--(BUSINESS WIRE)--Gloo Holdings, Inc. (Nasdaq: GLOO), a leading technology platform for the faith and flourishing ecosystem, today announced that it has commenced a proposed underwritten public offering of 7,000,000 shares of its Class A common stock. In connection with the proposed offering, Gloo expects to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of Class A common stock at the public offering price, less underwriting discounts and...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 03.07.2026 FTFX IE00BD5HBQ97 63,402.00 USD 1,715,153.74 27.052  ...
-

NATIXIS UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

Cirrus Introduces the TRAC10: A Purpose-Built Aircraft Engineered to Transform Professional Flight Training

DULUTH, Minn. & KNOXVILLE, Tenn.--(BUSINESS WIRE)--Cirrus (Cirrus Aircraft Ltd.), the best-selling high-performance single-engine piston aircraft manufacturer for over two decades, introduced the TRAC10, a newly designed flight training aircraft purpose-built for professional, collegiate, and career-oriented flight schools. The introduction of the TRAC10 expands the existing TRAC flight training aircraft product line. Featuring a turbocharged Rotax 916 iSc FADEC engine, spacious three-seat inte...
-

Stable Completes Sale of Portfolio of Revenue-Share Interests to Navigator Global Investments

NEW YORK--(BUSINESS WIRE)--Stable Asset Management (“Stable”), one of the largest and most-tenured GP stake builders focused on GP seed and acceleration investing, today announced the completion of its sale of a portfolio of minority, net revenue-share interests in alternative asset managers (the “Target Portfolio”) to Navigator Global Investments (ASX: NGI), a diversified alternative asset management company, for a total consideration of $190 million. The closing marks the establishment of a l...
-

Optimum Subsidiary Announces Final Results of Tender Offer for Shares of Optimum’s Class A Common Stock

NEW YORK--(BUSINESS WIRE)--CSC Investments II LLC, a Delaware limited liability company (“CSC Investments II”) and a wholly owned subsidiary of Optimum Communications, Inc. (NYSE: OPTU) (“Optimum”), today announced the final results of its tender offer, which expired at 5:00 p.m., New York City time, on June 30, 2026. Based on the final count by Equiniti Trust Company, LLC, the depositary for the tender offer (the “Depositary”), a total of 246,605,915 shares of Optimum’s Class A Common Stock, p...
-

Vontier Completes Divestiture of Teletrac Navman

RALEIGH, N.C.--(BUSINESS WIRE)--Vontier Completes Divestiture of Teletrac Navman...
-

PharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that its wholly owned subsidiary, FORUS Therapeutics Inc, has received a Notice of Compliance (NOC) authorizing BESREMi® (ropeginterferon alfa-2b) for the treatment of adults with polycythemia vera (PV). BESREMi® is expected to become commer...
-

NSTA and Tuva Expand Partnership to Advance Data Literacy in Science Education

RICHMOND, Va. & NEW YORK--(BUSINESS WIRE)--NSTA and Tuva announced an expanded partnership to co-facilitate professional learning that strengthens data literacy in science education....